Bill
SF 2371
SF 2371 proposes changes to Minnesota’s medical cannabis laws and program administration, potentially affecting eligibility, licensing, product standards, and oversight.
Status snapshot
- Bill number: SF 2371
- Title: Medical cannabis provisions modification
- Introduced: March 10, 2025
- Current status (as of provided record): Committee report — To pass and re‑referred to Commerce and Consumer Protection (April 7, 2025)
- Committee actions: Referred to Commerce and Consumer Protection (3/10); reported to pass as amended and re‑referred to Health and Human Services (3/20); reported to pass as amended and re‑referred to Judiciary and Public Safety (4/2); reported to pass and re‑referred to Commerce and Consumer Protection (4/7).
- Companion bill: HF 1672
What this bill is about (purpose)
- The bill’s title indicates it proposes changes to Minnesota’s medical cannabis laws and program administration. The intent (as implied by the title) is to modify statutory provisions that govern medical cannabis — likely addressing eligibility, product standards, distribution/licensing, regulatory oversight, or related program operations.
What is known and what is not
- The materials provided do not include the bill text or specific provisions. The committee history shows the bill has been amended and considered by multiple committees with jurisdiction over health, public safety, and commerce — which suggests the bill likely touches both health‑care and regulatory/commercial aspects of the medical cannabis program.
- For precise changes (statutory sections amended, specific eligibility criteria, product/labeling/testing requirements, licensing or fee changes, effective dates, and fiscal impacts), consult the enrolled/engrossed bill text and any fiscal note or author’s memo. The companion HF 1672 may contain parallel text useful for comparison.
Key areas likely affected (based on title and committee referrals)
- Patients: eligibility rules, qualifying conditions, registration process or patient protections.
- Health care providers: certification, oversight, or recordkeeping requirements.
- Dispensaries and registrants: licensing, retail rules, product types permitted, packaging/labeling, testing and quality standards.
- State agencies: Minnesota Department of Health and Commerce (regulatory duties, oversight, rulemaking authority).
- Public safety and legal system: enforcement provisions, criminal penalties or protections, law enforcement access to information.
- Payers/insurers: potential impacts on coverage or billing (if the bill addresses cost/authorization mechanisms).
Procedural notes and next steps
- The bill has moved through Health and Human Services, Judiciary and Public Safety, and Commerce and Consumer Protection committees, receiving amendments along the way. The April 7 committee report “To pass and re‑referred to Commerce and Consumer Protection” indicates the bill is advancing toward consideration by the Commerce committee with amendments already adopted in earlier committees.
- Next steps: committee floor action in Commerce, possible further amendments, committee vote, then floor debate and votes in the Senate. Track the fiscal note (cost/revenue impacts), hearing records, amendment language, and the companion HF 1672 for related House action.
Recommendations for readers
- To understand the bill’s specific legal and practical effects, review the full 1st/2nd engrossment bill text and the fiscal note (available on the Minnesota Legislature website) and compare with current statutes governing medical cannabis. Also review HF 1672 for the companion House proposal.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
